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Abstract
An exonic missense mutation, c.436C>G, in the PLP1 gene of a patient affected by the hypomyelinating
leukodystrophy, Pelizaeus–Merzbacher disease, has previously been found to be responsible for the alteration of the
canonical alternative splicing profile of the PLP1 gene leading to the loss of the longer PLP isoform. Here we show
that the presence of the c.436C>G mutation served to introduce regulatory motifs that appear to be responsible for
the perturbed splicing pattern that led to loss of the major PLP transcript. With the aim of disrupting the interaction
between the PLP1 splicing regulatory motifs and their cognate splicing factors, we designed an antisense
oligonucleotide-based in vitro correction protocol that successfully restored PLP transcript production in
oligodendrocyte precursor cells.
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Introduction
Pelizaeus–Merzbacher disease (PMD, MIM #312080) and X-
linked paraplegia type 2 (SPG2, MIM #312920) are allelic
hypomyelinating leukodystrophies caused by mutations in the
PLP1 gene (MIM #300401). The resulting clinical phenotypes
vary quite widely, ranging from the most severe connatal
phenotype, presenting at birth with nystagmus, severe
spasticity and hypotonia, to relatively mild cases of paraplegia
without mental retardation [1].
Duplication of a region of chromosome Xq22.2 containing the
PLP1 gene is the most frequent gene defect reported in PMD
(60-70% of cases). The complete deletion of the gene has
been reported only rarely as a cause of PMD/SPG2, while point
mutations have been identified in 20% of cases [2]. The PLP1
gene, which is mainly expressed in oligodendrocytes, encodes
a 4-pass transmembrane protein, termed PLP, which is the
most abundant protein in the myelin sheaths of the central
nervous system (CNS) [3]. A shorter protein isoform, DM20,
which lacks 35 amino acids from an intracellular domain, is
however generated by alternative splicing of the same primary
PLP1 gene transcript. Two competing 5’ donor splice sites,
residing within the 3’ portion of exon 3 (commonly termed exon
3B) are responsible for the alternative splicing [4]. The
biological roles of the PLP/DM20 proteins remain to be
clarified.
Despite their abundance in CNS myelin, myelination occurs
in knockout mice lacking the Plp1 gene, even though the
myelin produced exhibits reduced physical stability [5]. In
similar vein, male PMD patients harbouring a complete PLP1
gene deletion are relatively mildly affected [1]. However, male
PMD patients with a duplication of the PLP1 gene exhibit a
more severe phenotype, with severity increasing in the rarer
PMD patients with three or five PLP1 gene copies [6]. Point
mutations can give rise to a wide range of PMD/SPG2
phenotypes, the most severe being those that impair PLP and
DM20 folding and transport [7], whilst mutations with a limited
impact on PLP/DM20 protein structure are predicted to lead to
milder phenotypes. Among these mild mutations are those that
are located in exon 3B and which therefore involve PLP but not
DM20 [3].
We previously reported a mildly affected PMD patient with a
c.436C>G mutation located in exon 3B, and demonstrated that
this mutation, which would be expected to substitute leucine at
residue 146 with a valine (p.L146V), resulted instead in the loss
of the PLP isoform [8]. Although none of the regulatory splice
sites known to be involved in PLP/DM20 alternative splicing
regulation [9–11] was directly altered by the mutation,
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computational analysis suggested that c.436C>G leads to the
acquisition of exon splicing silencer (ESS) motifs [8]. In the
present report, we have extended this analysis by identifying
several splicing regulatory motifs created by the c.436C>G
mutation. In vitro experimentation subsequently confirmed the
predictions of the in silico hypotheses and suggested the
therapeutic potential of a specific antisense oligonucleotide to
correct the splicing defect by blocking the splicing regulatory
motifs.
Materials and Methods
Plasmid constructs, transfection and transcript
analysis
Plasmid constructs, derived from the pcDNA3.1/V5-His-
TOPO/LacZ vector (Invitrogen, San Diego, CA), with a
recombinant in-frame LacZ-PLP1-LacZ minigene containing
the genomic region between exons 2 and 4 of the PLP1 gene,
were previously prepared as wild-type and mutant (c.436C>G)
versions [8]. In the present study, a double mutant construct
was produced using the QuikChange II Site-Directed
Mutagenesis Kit (Stratagene Agilent, Santa Clara, CA, USA). In
accordance with the manufacturer’s instructions, specific
primers (146UPF: 5’-
GTTTGGGAAAATGGGAAGGACATCCCGACAAG-3’ and
146UPR: 5’-
CTTGTCGGGATGTCCTTCCCATTTTCCCAAAC-3’) were
used to introduce a further mutation (c.437T>A) adjacent to the
c.436C>G in the mutant plasmid. Thus, three versions of the
construct were used: the wild-type version (TGGCTAGG), the
naturally occurring mutant version (TGGGTAGG), and the
double mutant version (TGGGAAGG).
Wild-type and mutant plasmid constructs were transfected
into murine oligodendroglial Oli-neu cells [12] using the
Lipofectamine 2000 Transfection Reagent (Invitrogen)
according to the manufacturer’s instructions. SRSF6-specific
siRNA (Ambion, Austin, TX, USA) was cotransfected with the
mutant (c.436G) minigene into Oli-neu cells using the
lipofectamine 2000 Transfection Reagent (Invitrogen)
according to the manufacturer’s guidelines. A morpholino
antisense oligonucleotide (Gene Tools, Philomath, OR, USA)
(5’-GATGTCCTACCCATTTTCCCAAACA-3’) was designed by
the Gene Tools Oligo Design Support based upon the target
sequence surrounding the c.436G mutation. When morpholino
treatment was performed, various amounts of morpholino
oligonucleotide were added with the EndoPorter peptide
delivery system (Gene Tools) to the c.436G mutant minigene-
transfected Oli-neu cells as detailed in the Results and
Discussion section.
Transfected cells were harvested 48 hrs after transfection.
RNA was extracted using an RNeasy Plus Mini kit (Qiagen,
Valencia, CA, USA) and reverse transcribed using the
SuperScript® VILO™ cDNA Synthesis Kit (Invitrogen). To
avoid reverse transcription of endogenous Plp1 gene
transcripts from the Oli-neu cells, when specific priming was
required, first-strand cDNA synthesis was performed using the
SuperScript III First-Strand Synthesis System for RT-PCR
(Invitrogen), using a minigene-specific primer, LACT2R: 5’-
CGCGGGCCCTCTAGACTCGA -3’, according to Grossi et al.
[8]. RT-PCR from non-specifically primed reverse transcription
reactions was performed using both minigene-specific primers
31GF: 5’- TGATTTCAGCCGCGCTGTACTGG-3’ and LACT2R
[8].
To evaluate PLP transcript expression in morpholino-treated
Oli-neu cells transfected with the mutant plasmid construct, we
performed real-time PCR on cDNA reverse transcribed from
LACT2R-primed RNA using a PLP transcript-specific primer-
TaqMan probe set encompassing PLP1 exons 3 and 4 (P2),
and a PLP/DM20 transcripts-specific primer-TaqMan probe set
encompassing PLP1 exons 2 and 3 (P23B). Set P2 was used
as target, whereas set P23B was used as a reference [8].
Using this experimental approach, we were able to derive the
PLP/(DM20+PLP) ratio for cells treated with the morpholino
antisense oligonucleotide. cDNA samples, reverse transcribed
from LACT2R-primed RNAs, were run in quadruplicate, each
well containing the cDNA obtained from 10 ng RNA. A plasmid
containing the cDNA corresponding to PLP transcript isoform
was used to generate the standard curves for the P2 and the
P23B amplicons, respectively. Standards were run in duplicate.
Standard wells contained 10-2, 10-3, 10-4, 10-5, 10-6 and 10-7
ng/µl plasmid DNA.
Patient samples
All patient samples were obtained from the “Cell Line and
DNA Biobank from Patients Affected by Genetic Diseases” (G.
Gaslini Institute, Genoa) and processed as previously
described [8].
Ethical aspects
Following ethical guidelines, all cell and nucleic acid samples
stored in the Biobank were obtained for analysis and storage
with the patients’ (and/or a family member’s) written informed
consent. Consent was sought using a form approved by local
Ethics Committee.
Results and Discussion
In a previously studied PMD patient, we identified a PLP1
gene mutation, c.436C>G, located within exon 3B, the PLP-
specific region [8]. Since no RNA sample was available from
the patient, the functional effect of the c.436C>G mutation was
investigated using a recombinant LacZ-PLP1-LacZ in-frame
minigene containing a PLP1 gene exon 2 – exon 4 fragment
cloned into the pcDNA3.1/V5-His-TOPO/LacZ vector.
Comparison of the mRNAs generated through the transfection
of the wild-type (c.436C) and mutated (c.436G) versions of the
construct into Oli-neu cells, demonstrated that the c.436C>G,
expected to result in a missense p.L146V mutation, led instead
to the loss of the PLP transcript encoding the major isoform of
the PLP1 gene, whereas the shorter DM20 version of the PLP1
transcript was produced normally [8].
To investigate the apparent association between the c.
436C>G mutation and the observed alteration in the mRNA
splicing phenotype, we analyzed the mutated region in silico to
ascertain whether the mutation was responsible for the gain or
loss of splicing regulatory motifs. The ESEfinder 3.0 program
Oligonucleotide-Mediated Splicing Restoration
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[13,14] predicted that the c.436C>G mutation would create an
exonic splice enhancer (ESE, sequence TGGGTA, mutation
site underlined) specific for the SRSF6 splicing factor with a
score (2.70848) that was above the threshold level (2.676); the
corresponding score for the wild-type sequence (TGGCTA,
score: 0.40451) was considerably lower (Table 1 and Figure 1).
SRSF6 (also known as Srp55) is a splicing factor belonging to
the SR protein family which, by binding to ESEs, helps to
ensure the correct 5’ to 3’ linear order of exons in spliced
mRNA and also prevents exon skipping [15]. It is therefore
likely that SRSF6, by acting negatively on the splicing of exon
3B, plays a role in promoting PLP transcript production. The
Human Splicing Finder program (version 2.4.1) [16] and the
FAS-ESS web server [17] predicted the creation of two exonic
splice silencers (ESS), more specifically two FAS-hex3
hexamers (GGGTAG and GGTAGG) [16] (Figure 1). FAS-hex3
hexamers are potential exonic splicing silencer motifs [17].
They were found to be contained (and were overrepresented)
in decamers selected from a decamer random library by a cell-
based splicing reporter system specifically designed to detect
sequences with splicing silencer activity [17]. Fas-hex3
hexamers could therefore be responsible for the loss of the
PLP transcript isoform.
By means of in silico analysis, we determined that the
identified regulatory motifs (ESE, TGGGTA and ESS,
GGGTAG and GGTAGG), could be functionally altered by
introducing a second mutation (c.437T>A) immediately
adjacent to c.436C>G. Indeed, the resulting double mutant
(TGGGAA, GGGAAG and GGAAGG) not only abolished the
FAS-hex3 hexamer ESSs but also led to a significant reduction
Table 1. Output of ESEfinder program when the wild-type
and mutated PLP1 exon 3B sequences are compared.
Sequence Splicing factor motif Score Threshold score
TGGCTA (Wt) SRSF6 0.40451 2.676
TGGGTA (M)  2.70848  
TGGGAA (DM)  0.10328  
Legend: the mutated nucleotides are underlined; Wt = wild-type; M = mutant; DM =
double mutant.
Figure 1.  Schematic representation of the analysis of PLP1 gene structure with the ESEfinder, Human Splicing Finder and
FAS-ESS programs.  (a) Schematic representation of PLP1 gene structure (7 exons) and the alternative splicing of the PLP1 gene
into the major PLP1 transcript and a minor transcript encoding the shorter DM20 isoform, which differs only in terms of the latter half
of exon 3 (3B) which is post-transcriptionally spliced out. (b) Only part of the sequence of exon 3A (sequence in black type) and
exon 3B (sequence in red type) mutant PLP1 transcript is represented. The mutated nucleotide (c.436C>G) is underlined. According
to the ESEfinder 3.0 program, the c.436C>G change created an exonic splicing enhancer (EES, green trapezium), whereas Human
Splicing Finder version 2.4.1 and FAS-ESS web server predicted the creation of two exonic splicing silencers (ESS, purple
trapezia).
doi: 10.1371/journal.pone.0073633.g001
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in the ESE score (Table 1). Thus, the newly introduced c.
437T>A mutation would be predicted to abolish the effect of the
c.436C>G mutation on splicing thereby potentially restoring
PLP transcript production. To experimentally confirm this
postulate, we prepared by site-specific mutagenesis a double-
mutant version of the recombinant minigene construct and
transfected the three versions of the minigene [(wild-type
(TGGCTAGG), single mutant (TGGGTAGG) and double-
mutant (TGGGAAGG)] into Oli-neu cells. As shown in Figure 2,
the PLP transcript, which was present in cells transfected with
the wild-type minigene but absent in cells transfected with the
single mutant minigene, was expressed in cells transfected
with the double-mutant minigene. This served to confirm the
direct relationship between the presence of the c.436C>G
mutation-introduced regulatory motifs and the loss of the PLP
transcript isoform.
Having analyzed separately the potential effects of the ESE
and the ESS motifs, we surmise that SRSF6, by binding to the
ESE site, would direct the mRNA splicing phenotype towards
the PLP isoform. To test this hypothesis experimentally, we
cotransfected the mutant c.436C>G minigene construct and an
SRSF6-specific siRNA into Oli-neu cells. As predicted, the
mRNA splicing pattern, lacking the PLP transcript isoform, was
unmodified by the siRNA-mediated inhibition of the SRSF6-
ESE interaction (Figure S1). These results were consistent with
the hypothesis that the observed impact of the c.436C>G
mutation on splicing, leading to the loss of the PLP transcript
isoform, was mediated by the ESS motifs. We therefore
concluded that it was likely that the two newly created ESS
motifs played a role in the loss of the PLP isoform.
On the basis of this working hypothesis, we next investigated
the possibility of correcting in vitro the splicing defect caused
by the c.436G mutation by preventing the interaction of the
identified consensus sequences with their cognate splicing
factors. To this end, we employed an antisense oligonucleotide
designed to target the mutated region. When the antisense
oligonucleotide, specifically a morpholino oligonucleotide, was
introduced into Oli-neu cells transfected with the mutant
plasmid, restoration of PLP-transcript isoform expression was
observed. Although transcript rescue was not effectively
achieved using less than 10µm morpholino oligonucleotide (not
shown), satisfactory results were obtained with 10µM
morpholino delivered with different amounts of Endoporter
transfection reagent (from 2 to 10 µM) (Figure 3).
To evaluate quantitatively the morpholino-induced PLP
isoform transcript production, we performed real-time PCR
experiments using a primer-TaqMan probe-set specific for the
PLP transcript (P2) and a primer-TaqMan probe-set specific for
both the PLP and DM20 transcripts (P23B), as previously
described [8]. Following this procedure, we determined the
PLP/(PLP+DM20) ratio for the morpholino-treated Oli-neu cells
tranfected with the mutant construct; as shown in Table 2, we
obtained PLP/(PLP+DM20) ratios ranging from 0.079 to 0.122.
These values compare with a PLP/(PLP+DM20) ratio of 0.212
for Oli-neu cells transfected with the wild-type construct. Thus,
employing the morpholino oligonucleotide, we succeeded in
increasing the PLP/(DM20+PLP) ratio to a level which was
58% of the wild–type ratio. Although the presence of the PLP
and DM20 protein isoforms could not be directly confirmed
experimentally, we suspect that the translation of the detected
Figure 2.  RT-PCR from Oli-neu cells transfected with the wild-type and mutated minigenes.  Lane U: untransfected cells; lane
WT: cells transfected with the wild-type minigene construct; lane SM: cells transfected with the minigene construct harbouring the c.
436C>G mutation; lane DM: cells transfected with the minigene construct harbouring the double mutation [c.436C>T plus c.
437T>A]; lane C: negative (no template) control; lane M: φX174 DNA HaeIII-restricted molecular weight marker. The minigene-
specific primer 31GF/LACT2R-mediated RT-PCR products are 711 bp (PLP product) and 606 bp (DM20 product) in length,
respectively. The asterisk denotes samples transfected with the pcDNA3.1/V5-His-TOPO/LacZ-PLP1-LacZ vector.
doi: 10.1371/journal.pone.0073633.g002
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PLP and DM20 transcript might occur without blocking, owing
to the mRNA-morpholino interactions, as the region involved is
largely downstream of the ATG (approx. 1.9kb) translational
start site in the LacZ-PLP1-LacZ minigene. It is already known
that the blocking efficiency of morpholino oligonucleotides falls
dramatically as the distance of the binding region from the
initial ATG increases [18]. It should be noted that these results
were obtained using Oli-neu cells as recipients in all the
transfection experiments. The use of these mouse
oligodendrocyte precursor cells was deemed appropriate with a
view to mimicking the cellular environment in which PMD
displays its effects, and also avoiding potential biases in
splicing selection due to the action of tissue-specific factors.
The successful oligonucleotide-mediated restoration of the
major PLP transcript expression is important because the
ultimate cause of the disease in this patient is the absence of
the PLP isoform. However, unlike the situation with the DM20
transcript, restoration of the PLP transcript would be expected
to lead to the production of a PLP protein isoform harbouring
the p.L146V substitution. We neither know, nor can we predict,
Table 2. Real-time RT-PCR analysis of morpholino-treated
Oli-neu cells transfected with mutated (Mut) and wild-type
(Wt) PLP1 minigene constructs.
 Mut 2 4 6 8 10 Wt
PLP/(PLP+DM20) ratio 0.002 0.122 0.094 0.079 0.094 0.116 0.212
REC % 0.9 58 44 37 44 55 100
Legend: Columns 2, 4, 6, 8 and 10 indicate samples treated with 10 µM
morpholino oligonucleotide in 2, 4, 6, 8 and 10 µM Endoporter reagent,
respectively. The PLP/(PLP+DM20) ratio, obtained using the P2 and P23B sets of
primers and probes, is reported for each sample. Rec % denotes the proportion of
recovered PLP1 transcript expression as compared to the wild-type.
the likely clinical severity associated with the hypothetical PLP
p.L146V mutation as compared with the complete absence of
the PLP isoform. The p.L146V mutation would be located
within the cytoplasmic loop of PLP. The analysis of the extent
of evolutionary conservation of this loop, flanking the Leu 146
residue, in 7 orthologous PLP proteins showed that it has been
conserved in amphibians but not in fish, suggesting that the
PLP isoform is typical of higher vertebrates (Table S1) [19]. In
general, mutations located within this loop, and, in particular,
mutations located in amino acid residues in the vicinity of
Leu146, are not associated with severe clinical phenotypes.
Indeed, the closest reported missense mutations, H147Y [20]
and H140Y [21], both of which are predicted to lead to the
production of a mutant PLP isoform, have been reported in
patients affected by a relatively mild SPG2 clinical phenotype.
In addition, mutations residing within the cytoplasmic loop do
not appear to exert a particularly detrimental impact on the
general structure of the PLP protein, in particular on the
tetraspan structure, whose integrity prevents retention of the
protein in the endoplasmic reticulum (ER) [22] with consequent
potential activation of the unfolded protein response (UPR).
The p.L146V mutation would not be predicted to alter any of
the previously proposed putative ER-retention signals: namely,
the fourth transmembrane domain of the PLP protein [23], and
a heptapeptide within the intracellular loop [24]. Finally, the
conservative replacement of the aliphatic hydrophobic side
chain of Leu with the slightly smaller aliphatic hydrophobic side
chain of Val is not inconsistent with a mild clinical phenotype.
Taking the above considerations together, we would
therefore predict that the p.L146V mutation should not give rise
to a major structural alteration of PLP nor is it likely that it
would result in the retention of the PLP protein isoform in the
ER. We would therefore predict that the presence of the
L146V-mutated PLP isoform would be less detrimental to the
individual harbouring it than would the complete absence of the
Figure 3.  Analysis of morpholino treatment: RT-PCR from minigene-transfected morpholino-treated Oli-neu cells.  RNA
was extracted from cells transfected with the wild-type (Wt) and mutant (c.436C>G) minigene constructs (Mut, 2, 4, 6, 8, 10).
Samples 2, 4, 6, 8 and 10 were treated with the morpholino oligonucleotide, whereas samples Mut and Wt were untreated. Treated
cells received 10 mM morpholino oligonucleotide in 2, 4, 6, 8, 10 mM Endoporter reagent; lane C: no template control; lane M:
φX174 DNA HaeIII restricted molecular weight marker. The minigene-specific primer 31GF/LACT2R-mediated RT-PCR products
are 711 bp (PLP product) and 606 bp (DM20 product) in length, respectively.
doi: 10.1371/journal.pone.0073633.g003
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PLP isoform. If this turns out to be the case, then our
oligonucleotide-mediated in vitro correction strategy should
have a high likelihood of being successful in ameliorating the
clinical phenotype of the patient as part of a sequence-targeted
therapeutic approach in this case of PMD.
Supporting Information
Figure S1.  siRNA-mediated inhibition of the SRSF6-ESE
interaction.
(TIF)
Table S1.  Evolutionary comparison of the PLP1 protein
intracellular loop flanking the L146V missense mutation
with their orthologous counterparts in seven vertebrates.
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